Experienced in Caffey Disease

Dr. Robert Z. Orlowski

Hematology Oncology | Oncology
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Offers Telehealth
33 Years of Experience
Experienced in Caffey Disease
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Orlowski is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Orlowski has been practicing medicine for over 33 years and is rated as an Experienced provider by MediFind in the treatment of Caffey Disease. His top areas of expertise are Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 344 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Memorial Hermann Hospital System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMSA
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 1/Phase 2
Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Drug, Other
Study Drugs: Ixazomib Citrate, Lenalidomide
Study Phase: Phase 2
Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients With Relapsed/Refractory Myeloma
Phase 1/1b Study of the Efficacy and Safety of the Combination of Panobinostat + Carfilzomib in Patients With Relapsed/Refractory Myeloma
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Panobinostat
Study Phase: Phase 1
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 03, 2021
Intervention Type: Drug
Study Drug: MIK665
Study Phase: Phase 1
Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma
Phase II Study of Bortezomib (PS-341) and Pegylated Liposomal Doxorubicin as Initial Therapy for Adult Patients With Symptomatic Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: July 16, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
View 6 Less Clinical Trials

344 Total Publications

Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Genomics Define Malignant Transformation in Myeloma Precursor Conditions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2025
Similar Doctors
Advanced in Caffey Disease
Dr. Craig A. Kovitz
Hematology Oncology | Oncology | Hematology
Advanced in Caffey Disease
Dr. Craig A. Kovitz
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances

Craig Kovitz is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Kovitz is rated as a Distinguished provider by MediFind in the treatment of Caffey Disease. His top areas of expertise are Acute Promyelocytic Leukemia, Upper Tract Urothelial Carcinoma (UTUC), Paget Disease of the Breast, and Small Cell Lung Cancer (SCLC).

Experienced in Caffey Disease
Dr. Celyne L. Bueno-Hume
Hematology Oncology | Hematology | Oncology
Experienced in Caffey Disease
Dr. Celyne L. Bueno-Hume
Hematology Oncology | Hematology | Oncology

MD Anderson

1515 Holcombe Blvd, 
Houston, TX 
 (0.6 miles away)
713-794-5446
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Celyne Bueno-Hume is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Bueno-Hume is rated as a Distinguished provider by MediFind in the treatment of Caffey Disease. Her top areas of expertise are Oral Squamous Cell Carcinoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Bueno-Hume is currently accepting new patients.

Experienced in Caffey Disease
Dr. Ana M. Aparicio
Hematology Oncology | Oncology | Hematology
Experienced in Caffey Disease
Dr. Ana M. Aparicio
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.1 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ana Aparicio is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Aparicio is rated as a Distinguished provider by MediFind in the treatment of Caffey Disease. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Orchiectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orlowski's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile